APO Research
Talk to an analyst

APO RESEARCH · REPORT

Nivolumab

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Nivolumab Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

23 December 2025177 pages

Choose your research edition.

Industry ResearchNivolumab Industry Research Report 2026110 pages · $2,950 USDIndustry Growth & TrendsGlobal Nivolumab Industry Growth and Trends Forecast to 203279 pages · $3,450 USDMarket StructureGlobal Nivolumab Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032177 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nivolumab Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Nivolumab Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Nivolumab market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Nivolumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Nivolumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Nivolumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Nivolumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Nivolumab include Ono Pharmaceutical and Bristol-Myers Squibb among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Nivolumab market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Nivolumab and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Nivolumab sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Nivolumab market size, projected growth trends, production technologies, key applications, and end-use industries.

Nivolumab Segment by Company

Ono Pharmaceutical

Bristol-Myers Squibb

Nivolumab Segment by Type

Injection 4mL

Injection 10mL

Nivolumab Segment by Application

Metastatic Squamous NSCLC

Metastatic Melanoma

Renal Cell Carcinoma

Classical Hodgkin Lymphoma

Unresectable Melanoma

Others

Nivolumab Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nivolumab market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nivolumab and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nivolumab.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Nivolumab market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Nivolumab manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Nivolumab in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Nivolumab in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Nivolumab Industry Trends Table 2. Nivolumab Industry Drivers Table 3. Nivolumab Industry Opportunities and Challenges Table 4. Nivolumab Industry Restraints Table 5. Global Nivolumab Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Nivolumab Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Nivolumab Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Nivolumab Sales Market Share by Manufacturers Table 9. Global Nivolumab Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Nivolumab Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Nivolumab Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Nivolumab Manufacturers, Product Type & Application Table 13. Global Nivolumab Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Nivolumab by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Injection 4mL Table 17. Major Manufacturers of Injection 10mL Table 18. Global Nivolumab Sales by Type 2021 VS 2025 VS 2032 (k units) Table 19. Global Nivolumab Sales by Type (2021-2026) & (k units) Table 20. Global Nivolumab Sales by Type (2027-2032) & (k units) Table 21. Global Nivolumab Sales Market Share by Type (2021-2026) Table 22. Global Nivolumab Sales Market Share by Type (2027-2032) Table 23. Global Nivolumab Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Nivolumab Revenue by Type (2021-2026) & (k units) Table 25. Global Nivolumab Revenue by Type (2027-2032) & (k units) Table 26. Global Nivolumab Revenue Market Share by Type (2021-2026) Table 27. Global Nivolumab Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Metastatic Squamous NSCLC Table 29. Major Manufacturers of Metastatic Melanoma Table 30. Major Manufacturers of Renal Cell Carcinoma Table 31. Major Manufacturers of Classical Hodgkin Lymphoma Table 32. Major Manufacturers of Unresectable Melanoma Table 33. Major Manufacturers of Others Table 34. Global Nivolumab Sales by Application 2021 VS 2025 VS 2032 (k units) Table 35. Global Nivolumab Sales by Application (2021-2026) & (k units) Table 36. Global Nivolumab Sales by Application (2027-2032) & (k units) Table 37. Global Nivolumab Sales Market Share by Application (2021-2026) Table 38. Global Nivolumab Sales Market Share by Application (2027-2032) Table 39. Global Nivolumab Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 40. Global Nivolumab Revenue by Application (2021-2026) & (k units) Table 41. Global Nivolumab Revenue by Application (2027-2032) & (k units) Table 42. Global Nivolumab Revenue Market Share by Application (2021-2026) Table 43. Global Nivolumab Revenue Market Share by Application (2027-2032) Table 44. Global Nivolumab Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 45. Global Nivolumab Sales by Region (2021-2026) & (k units) Table 46. Global Nivolumab Sales Market Share by Region (2021-2026) Table 47. Global Nivolumab Sales Forecasted by Region (2027-2032) & (k units) Table 48. Global Nivolumab Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Nivolumab Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 50. North America Nivolumab Sales by Country (2021-2026) & (k units) Table 51. North America Nivolumab Sales by Country (2027-2032) & (k units) Table 52. Europe Nivolumab Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 53. Europe Nivolumab Sales by Country (2021-2026) & (k units) Table 54. Europe Nivolumab Sales by Country (2027-2032) & (k units) Table 55. Asia Pacific Nivolumab Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Asia Pacific Nivolumab Sales by Country (2021-2026) & (k units) Table 57. Asia Pacific Nivolumab Sales by Country (2027-2032) & (k units) Table 58. South America, Middle East and Africa Nivolumab Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 59. South America, Middle East and Africa Nivolumab Sales by Country (2021-2026) & (k units) Table 60. South America, Middle East and Africa Nivolumab Sales by Country (2027-2032) & (k units) Table 61. Global Nivolumab Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Nivolumab Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Nivolumab Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Nivolumab Revenue Market Share by Region (2021-2026) Table 65. Global Nivolumab Revenue Market Share by Region (2027-2032) Table 66. Ono Pharmaceutical Company Information Table 67. Ono Pharmaceutical Business Overview Table 68. Ono Pharmaceutical Nivolumab Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Ono Pharmaceutical Nivolumab Product Portfolio Table 70. Ono Pharmaceutical Recent Development Table 71. Bristol-Myers Squibb Company Information Table 72. Bristol-Myers Squibb Business Overview Table 73. Bristol-Myers Squibb Nivolumab Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Bristol-Myers Squibb Nivolumab Product Portfolio Table 75. Bristol-Myers Squibb Recent Development Table 76. Key Raw Materials Table 77. Raw Materials Key Suppliers Table 78. Nivolumab Distributors List Table 79. Nivolumab Customers List Table 80. Research Programs/Design for This Report Table 81. Authors List of This Report Table 82. Secondary Sources Table 83. Primary Sources List of Figures Figure 1. Nivolumab Product Image Figure 2. Global Nivolumab Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nivolumab Market Size (2021-2032) & (US$ Million) Figure 4. Global Nivolumab Sales (2021-2032) & (k units) Figure 5. Global Nivolumab Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Nivolumab Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Injection 4mL Image Figure 9. Injection 10mL Image Figure 10. Global Nivolumab Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 11. Global Nivolumab Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Nivolumab Sales Market Share by Type (2021-2032) Figure 13. Global Nivolumab Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Nivolumab Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Nivolumab Revenue Market Share by Type (2021-2032) Figure 16. Metastatic Squamous NSCLC Image Figure 17. Metastatic Melanoma Image Figure 18. Renal Cell Carcinoma Image Figure 19. Classical Hodgkin Lymphoma Image Figure 20. Unresectable Melanoma Image Figure 21. Others Image Figure 22. Global Nivolumab Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Nivolumab Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Nivolumab Sales Market Share by Application (2021-2032) Figure 25. Global Nivolumab Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 26. Global Nivolumab Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Nivolumab Revenue Market Share by Application (2021-2032) Figure 28. North America Nivolumab Sales and Growth Rate (2021-2032) & (k units) Figure 29. North America Nivolumab Sales Market Share by Country (2021-2032) Figure 30. U.S. Nivolumab Sales and Growth Rate (2021-2032) & (k units) Figure 31. Canada Nivolumab Sales and Growth Rate (2021-2032) & (k units) Figure 32. Mexico Nivolumab Sales and Growth Rate (2021-2032) & (k units) Figure 33. Europe Nivolumab Sales and Growth Rate (2021-2032) & (k units) Figure 34. Europe Nivolumab Sales Market Share by Country (2021-2032) Figure 35. Germany Nivolumab Sales and Growth Rate (2021-2032) & (k units) Figure 36. France Nivolumab Sales and Growth Rate (2021-2032) & (k units) Figure 37. U.K. Nivolumab Sales and Growth Rate (2021-2032) & (k units) Figure 38. Italy Nivolumab Sales and Growth Rate (2021-2032) & (k units) Figure 39. Netherlands Nivolumab Sales and Growth Rate (2021-2032) & (k units) Figure 40. Asia Pacific Nivolumab Sales and Growth Rate (2021-2032) & (k units) Figure 41. Asia Pacific Nivolumab Sales Market Share by Country (2021-2032) Figure 42. China Nivolumab Sales and Growth Rate (2021-2032) & (k units) Figure 43. Japan Nivolumab Sales and Growth Rate (2021-2032) & (k units) Figure 44. South Korea Nivolumab Sales and Growth Rate (2021-2032) & (k units) Figure 45. Southeast Asia Nivolumab Sales and Growth Rate (2021-2032) & (k units) Figure 46. India Nivolumab Sales and Growth Rate (2021-2032) & (k units) Figure 47. Australia Nivolumab Sales and Growth Rate (2021-2032) & (k units) Figure 48. South America, Middle East and Africa Nivolumab Sales and Growth Rate (2021-2032) & (k units) Figure 49. South America, Middle East and Africa Nivolumab Sales Market Share by Country (2021-2032) Figure 50. Brazil Nivolumab Sales and Growth Rate (2021-2032) & (k units) Figure 51. South Africa Nivolumab Sales and Growth Rate (2021-2032) & (k units) Figure 52. Saudi Arabia Nivolumab Sales and Growth Rate (2021-2032) & (k units) Figure 53. Turkey Nivolumab Sales and Growth Rate (2021-2032) & (k units) Figure 54. Argentina Nivolumab Sales and Growth Rate (2021-2032) & (k units) Figure 55. UAE Nivolumab Sales and Growth Rate (2021-2032) & (k units) Figure 56. Egypt Nivolumab Sales and Growth Rate (2021-2032) & (k units) Figure 57. Chile Nivolumab Sales and Growth Rate (2021-2032) & (k units) Figure 58. Global Nivolumab Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Nivolumab Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Nivolumab Revenue (2021-2032) & (US$ Million) Figure 61. North America Nivolumab Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Nivolumab Revenue (2021-2032) & (US$ Million) Figure 63. Europe Nivolumab Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Nivolumab Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Nivolumab Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Nivolumab Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Nivolumab Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Nivolumab Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Nivolumab Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Injection 4mL
  • Injection 10mL
Applications
  • Metastatic Squamous NSCLC
  • Metastatic Melanoma
  • Renal Cell Carcinoma
  • Classical Hodgkin Lymphoma
  • Unresectable Melanoma
  • Others
Companies covered
  • Ono Pharmaceutical
  • Bristol-Myers Squibb

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Nivolumab Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Nivolumab Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Nivolumab Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Nivolumab Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Nivolumab Market Dynamics
  1. 2.1 Nivolumab Industry Trends
  2. 2.2 Nivolumab Industry Drivers
  3. 2.3 Nivolumab Industry Opportunities and Challenges
  4. 2.4 Nivolumab Industry Restraints
3 Nivolumab Market by Manufacturers
  1. 3.1 Global Nivolumab Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Nivolumab Sales by Manufacturers (2021-2026)
  3. 3.3 Global Nivolumab Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Nivolumab Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Nivolumab Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Nivolumab Manufacturers, Product Type & Application
  7. 3.7 Global Nivolumab Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Nivolumab Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Nivolumab Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Nivolumab Tier 1, Tier 2, and Tier 3
4 Nivolumab Market by Type
  1. 4.1 Nivolumab Type Introduction
  2. 4.1.1 Injection 4mL
  3. 4.1.2 Injection 10mL
  4. 4.2 Global Nivolumab Sales by Type
  5. 4.2.1 Global Nivolumab Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Nivolumab Sales by Type (2021-2032)
  7. 4.2.3 Global Nivolumab Sales Market Share by Type (2021-2032)
  8. 4.3 Global Nivolumab Revenue by Type
  9. 4.3.1 Global Nivolumab Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Nivolumab Revenue by Type (2021-2032)
  11. 4.3.3 Global Nivolumab Revenue Market Share by Type (2021-2032)
5 Nivolumab Market by Application
  1. 5.1 Nivolumab Application Introduction
  2. 5.1.1 Metastatic Squamous NSCLC
  3. 5.1.2 Metastatic Melanoma
  4. 5.1.3 Renal Cell Carcinoma
  5. 5.1.4 Classical Hodgkin Lymphoma
  6. 5.1.5 Unresectable Melanoma
  7. 5.1.6 Others
  8. 5.2 Global Nivolumab Sales by Application
  9. 5.2.1 Global Nivolumab Sales by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Nivolumab Sales by Application (2021-2032)
  11. 5.2.3 Global Nivolumab Sales Market Share by Application (2021-2032)
  12. 5.3 Global Nivolumab Revenue by Application
  13. 5.3.1 Global Nivolumab Revenue by Application (2021 VS 2025 VS 2032)
  14. 5.3.2 Global Nivolumab Revenue by Application (2021-2032)
  15. 5.3.3 Global Nivolumab Revenue Market Share by Application (2021-2032)
6 Global Nivolumab Sales by Region
  1. 6.1 Global Nivolumab Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Nivolumab Sales by Region (2021-2032)
  3. 6.2.1 Global Nivolumab Sales by Region (2021-2026)
  4. 6.2.2 Global Nivolumab Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Nivolumab Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Nivolumab Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Nivolumab Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Nivolumab Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Nivolumab Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Nivolumab Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Nivolumab Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Nivolumab Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Nivolumab Revenue by Region
  1. 7.1 Global Nivolumab Revenue by Region
  2. 7.1.1 Global Nivolumab Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Nivolumab Revenue by Region (2021-2026)
  4. 7.1.3 Global Nivolumab Revenue by Region (2027-2032)
  5. 7.1.4 Global Nivolumab Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Nivolumab Revenue (2021-2032)
  8. 7.2.2 North America Nivolumab Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Nivolumab Revenue (2021-2032)
  11. 7.3.2 Europe Nivolumab Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Nivolumab Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Nivolumab Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Nivolumab Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Nivolumab Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Ono Pharmaceutical
  2. 8.1.1 Ono Pharmaceutical Company Information
  3. 8.1.2 Ono Pharmaceutical Business Overview
  4. 8.1.3 Ono Pharmaceutical Nivolumab Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Ono Pharmaceutical Nivolumab Product Portfolio
  6. 8.1.5 Ono Pharmaceutical Recent Developments
  7. 8.2 Bristol-Myers Squibb
  8. 8.2.1 Bristol-Myers Squibb Company Information
  9. 8.2.2 Bristol-Myers Squibb Business Overview
  10. 8.2.3 Bristol-Myers Squibb Nivolumab Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bristol-Myers Squibb Nivolumab Product Portfolio
  12. 8.2.5 Bristol-Myers Squibb Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Nivolumab Value Chain Analysis
  2. 9.1.1 Nivolumab Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Nivolumab Production Mode & Process
  6. 9.2 Nivolumab Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Nivolumab Distributors
  9. 9.2.3 Nivolumab Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst